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AIMS & OBJECTIVES:  
To assess the immediate loco regional response rates and to assess the toxicity profile 
of sequential therapy with three cycles of induction PFT followed by Concurrent Chemo 
Radiation with weekly Cisplatin in Locally Advanced Head and Neck Cancers. 
MATERIALS AND METHODOLOGY: 
30 consecutive patients with locally advanced head and neck cancers attending the 
OPD at our institute were included in the study. All patients were treated with 3 cycles of 
Induction chemotherapy with PFT regimen (Paclitaxel 175mg/m2 Day1, Cisplatin 100 mg/m² 
split to (Day 1-3), 5-FU 750 mg/m² Day 1 to 3) every 21 days. The patients were then taken 
up for concurrent chemo radiation (66 Gy RT along with weekly Cisplatin 40mg/sq.m.). The 
immediate loco regional response rates were assessed by clinical and radiological imaging. 
The toxicity profile of the treatment was assessed with RTOG acute morbidity scoring 
criteria and CTCAE Version 4.  
 
RESULTS:  
30 patients (3 female) were recruited for the study. Among them 3 were laryngeal 
cancer patients and the hypo pharyngeal, oropharyngeal and the oral cavity cancers were 9 
each. 63% of them had complete response and 30% had partial response. The sub-sites of 
hypopharynx and the oropharynx had the best outcomes from this treatment protocol. 2 
patients did not complete the planned treatment.11 patients had grade 3 leukopenia and 2 
patients had grade 4/febrile neutropenia. There were no grade 3 thrombocytopenia in the 
study group. 
CONCLUSIONS:  
Sequential therapy with three cycles of induction PFT followed by concurrent chemo 
radiation is a feasible alternative for moderately advanced and very advanced head and neck 
cancer. Patient selection and supportive care during treatment are very important for 
successful outcome.   
  
 
 
 
 
 
 
 
 
 
INTRODUCTION 
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1. INTRODUCTION 
 
Face is what makes the man. It distinguishes us and gives us a unique 
identity. Face is what helps us human beings to socialize. It helps us to 
communicate the thoughts of our minds and hearts through expressions and 
spoken words. Perhaps this unique ability to express ourselves vocally or 
by just facial expression is the single most important thing that separates us 
human beings from all the other species on this planet.  The very essences 
of our lives, air and nutrition reach us through the organs in the face. 
Besides this, it is also the gateway to the special senses such as vision, 
smell, hearing and taste.  
   
In this context, cancers involving the face result in a variety of problems 
for the patient related to the functions of the face as written above. Head 
and neck region cancers represent a heterogeneous group of cancers 
involving the various structures in the region. It comprises the cancers in 
the following anatomical regions including nasal cavity, nasopharynx, oral 
cavity, oropharynx, hypopharynx, the larynx, the salivary glands and the 
para-nasal sinuses.   
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EPIDEMIOLOGY: 
Every year around 5 million new cases of head and neck cancers are 
diagnosed worldwide. It accounts for 10% of all the malignancies 
diagnosed and is the sixth most common cancer in the world.1, 2 It is one of 
those cancers which can have a devastating effect on the individual by way 
of functional and cosmetic consequences. It is a significant public health 
problem afflicting the developing countries. The incidence of head and 
neck cancers have come down in the developed countries with the 
awareness that smoking is one of the commonest causes and the 
subsequent decrease in smokers.3 However, the incidence has not shown a 
decline in the developing countries despite steps to create awareness.   
 
With regard to India, it is one of the commonest cancers in our country 
due to the widespread use of tobacco products in its various forms.4 Oral 
cavity cancer was the commonest and  the commonest sub site to be 
involved was the tongue.5 This is despite the steps taken by our 
governments to create awareness with graphic warning labels on the 
tobacco products and a ban on the advertisements for tobacco products6. 
What was once a problem of the adults, tobacco addiction has now become 
a common thing among youngsters resulting in the incidence of cancer at a 
very young age.  
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In our institute too, head and neck cancers constitute the majority of 
cases registered in our OPD. Majority of them are squamous cell 
carcinomas (~95%) with other histology making up the remaining. Nearly 
three quarters of them present in the locally advanced stage. Only around 
20 to 25% of the cases present in the early stages. Most of them are 
tobacco users either in smoked form such as cigarettes, beedis or in 
smokeless forms such as pan etc.  
 
AETIOLOGY: 
 The state of our health has become increasingly dependent on our 
environment and our lifestyle habits. This is more so in the case of head 
and neck cancers. The various etiological factors of head and neck cancers 
point to the impact, life style changes in past century had on our health. 
The incidence of head and neck cancers keep increasing with the increase 
in age. Of late the incidence is also increasing in younger age groups too. 
This may be due to behavioral changes in this age group. 
 
1. Smoking:  Tobacco is by far the most important etiological 
factor7, 8. Smoking of tobacco in the form of cigarettes, cigars, 
beedis, and loose tobacco in pipes is common in our country. 
Beedis are more dangerous than cigarettes. Also reversed 
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smoking, common in some regions are associated with increased 
incidences. 
 
2. Smokeless Tobacco7, 8: In our country and in the South Asia 
region, smokeless tobacco forms such as pan, ghutka, khaini etc., 
play a very important role. It is also used in combination with 
other irritants such as betel leaf, arecanut, slaked lime etc. The 
age group of the users of these products is ever decreasing. This 
is despite the various prohibitory orders in effect such as 
prohibition of sale of tobacco products near educational 
institutions etc. 
 
3. Alcohol7, 8: Alcohol intake also has long been associated with the 
incidence of H & N cancers. Consumption of alcohol is a 
synergistic factor along with tobacco use. 
 
4. Human Papilloma Virus9: HPV is associated with around 35% 
of all head and neck cancers. It is more commonly associated 
with oropharyngeal cancers especially in the case of tonsillar 
cancers. HPV 16 is the most common virus associated with 
incidence of oral cancers in around 22% and the next most 
commonly associated is HPV 18 in around 15%.10-13  
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5. Deficient diet7, 8: Deficiency of certain nutrients has been 
implicated with the development of oral cancers although this is 
controversial. This is attributed to be the reason for around 10 – 
15 % of oral cancers in European countries.  
 
6. Others: other common factors implicated in the development of 
these cancers are sharp tooth, spicy foods, sub mucous fibrosis, 
aromatic hydrocarbons, asbestos, wood dust, nickel, chromium, 
heat fumes etc.  
 
PREMALIGNANT CONDITIONS:  
These are conditions which have chance of progression to invasive 
malignancies.14 But a vast majority of head and neck cancer patients do not 
present with any identifiable premalignant lesions and they may not 
represent an opportunity to reduce the incidence of these cancers. 
 
1. Leukoplakia: Oral leukoplakia (a white mucosal patch or plaque) is 
the commonest premalignant lesion of the oral cavity, and is a 
marker of an increased risk of cancer anywhere in the oral cavity. It 
is associated with smoking. They have a very low rate of progression 
to malignant changes. They also resolve with cessation of smoking.15 
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2. Erythroplakia: Reddish discolouration of the mucosa that is 
associated with more risk of malignant transformation than that of 
leukoplakia up to 15%.   
Other lesions considered to be premalignant lesions are oral lichen 
planus, oral mucous fibrosis, epidermolysis bullosa, discoid lupus 
erythematosus etc.16 
 
HISTOLOGY:  
 The most common histology in head and neck cancers are squamous 
cell carcinomas arising from the epithelial lining of the upper aero 
digestive tract. Differentiation of these tumors varies from site to site. The 
cancers from sub sites of the oral cavity are usually well differentiated, in 
more than 95%. Cancers of the oropharynx are usually moderately 
differentiated in around 65%. Cancers of the larynx are usually well 
differentiated and that of the hypopharynx are moderate to poorly 
differentiated. Less common variants of the squamous cell carcinomas 
include verrucous carcinomas, which are very well differentiated and have 
warty gross appearance.17 It is very difficult to identify the malignancy in 
this variety. Another variant is the squamous cell carcinomas with spindle 
cells features. The significance of the spindle cell in this variety is 
debatable. Other histologies arise from minor salivary glands, lymphoid 
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follicles in the waldeyers ring, neuroendocrine (small cell) tumors, 
sarcomas etc. 
 
SYMPTOMS: 
The patients present with a wide range of symptoms such as, pain, 
swelling in the neck, non healing ulcers in the oral cavity, proliferative 
growth in the tongue, difficulty in swallowing, difficulty in breathing, 
hoarseness of voice etc. The symptoms give an indication as to the primary 
site of involvement and also to the extent of the disease. They also present 
with emergencies such as bleeding from the lesion, stridor etc.  The wide 
range of presentation influences the treatment considerations of the treating 
oncologist. 
 
NATURAL HISTORY: 
 Head and neck cancers are mostly loco regional diseases with the 
primary tumor slowly increasing in size and involving the adjacent 
structures. Certain sub sites in this region have vital structures as adjacent 
structures. For instances in hypo pharyngeal and laryngeal cancers the 
airway may be compromised either as direct result of tumor obstructing the 
airway or as a result of the tumor encroaching on to nervous structures. 
This will result in the patient presenting with stridor as a symptom to the 
emergency room. Oropharyngeal, hypo pharyngeal and laryngeal cancers 
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may compromise the digestive tract resulting in difficulty in food intake or 
painful swallowing. This will have an adverse impact on further treatment 
plans for the patient as he may be malnourished at the time of presentation. 
Cancers of the oral cavity can spread to involve the deep extrinsic muscles 
of the tongue resulting in ankyloglossia. Cancers of the buccal mucosa may 
erode the entire cheek up to skin resulting in leakage of food. Cancers of 
the head and neck region, particularly of the tonsil may erode onto a blood 
vessel and result in torrential bleeding which is again an emergency. Oral 
cavity cancers can spread and erode adjacent bony structures resulting in a 
change in the primary modality of treatment. There can also be perineural 
invasion which is an adverse prognostic factor. 
 As the size of the primary increases, the incidence of regional spread 
to involve the draining lymph nodes increases. Each sub site involves 
certain levels of the cervical nodes more commonly. The hypo pharyngeal 
cancers most commonly involve the Level III and IV nodes. The 
oropharyngeal cancers most commonly involve the Level II and III nodes, 
whereas the cancers of the buccal mucosa usually spread to the Level Ib 
region. The Level Ia is usually involved only in cancers of the lip and in 
cancers involving the tip of the tongue.  
 Literature review claims the incidence of distant metastasis in head 
and neck cancers to be around 15 – 20%18-19. But most patients die of loco 
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regional disease, as around 50 – 60% of those who are cured with 
combined modality therapies recur within the first 2 years of follow up. 
  
WORKUP: 20, 21 
1. History of symptoms. 
2. Thorough clinical examination of the primary site and the regional 
lymph nodes. Thorough examination of the entire head and neck 
region to rule out second primary malignancies has to be carried out. 
Indirect and video laryngoscopies, esophagoscopy in case of the post 
cricoid region cancers to rule out involvement of cervical esophagus.  
3. Biopsy of the primary tumor.  
4. Imaging studies: Computed Tomography (CT) of the Neck 
extending from the base of skull to the root of the neck. 
5. Magnetic Resonance Imaging (MRI): Soft tissue delineation is better 
in MRI. 
6. Chest X ray to rule out distant metastasis in the case of locally 
advanced head and neck cancers. 
7. Basic Metabolic Panel: Renal function tests and Liver function tests. 
8. Complete Blood Count. 
9. Assessment of anesthetic fitness if decided for surgery as modality 
of treatment. 
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10. HPV DNA or HPV – prognostic information in case of 
oropharyngeal cancers. 
 
PROGNOSTIC FACTORS: 
 Prognosis of patients with head and neck cancers depends most 
importantly on the stage of the disease at the time of initial presentation.22 
Involvement of nodes in head and neck cancers upgrades it to stage III and 
also the survival of these patients is decreased by as much as 50%. 
Involvement of regional lymph nodes and also advanced T stages have 
higher incidence of loco regional recurrences and also distant metastasis. 
They also require multimodality treatment than the early stage cancers in 
which single modality will achieve cure in more than 90% of cancers. Even 
with these aggressive approaches more than 50 – 60% will fail the 
treatment and have local recurrences and in the rare cases develop distant 
metastasis. Death in such cases is usually due to loco regional recurrences. 
Other well-known prognostic factors are perineural invasion, positive or 
close margins after resection of the primary, extra caspular extension23-24, 
depth of invasion, extent of nodal involvement22, 25.  
 Nutrition of the patient at presentation also plays a very important 
role26, 27. Malnourishment rules out implementation of aggressive 
multimodality therapies which are the order of treatment in locally 
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advanced cancers and are straight away put on palliative treatment or on 
supportive care. 
 
MOLECULAR BIOMARKERS: 
1. EGFR overexpression: 
EGFR receptors are overexpressed in over 95% of the 
squamous cell carcinomas of the head and neck. It has been 
corroborated as a worse prognostic factor. However it also gives a 
therapeutic target in manipulating the receptor pathways in cancer 
cells. Several targeted agents, monoclonal antibodies like cetuximab 
are available in the market and also have shown benefit in the 
advanced stages.28 
2. Tyrosine kinases: 
These are the downstream kinases responsible for several 
functional pathways in tumor and normal cells. They also provide a 
target for manipulation with tyrosine kinase inhibitors (TKI) like 
geftinib and erlotinib. 
3. TP53 mutation: 
The frequent observation of p53 gene deletion or mutation in 
head and neck cancer has prompted the development of gene 
therapy. Mutation of the p53 tumour suppressor gene has been 
associated with field cancerization, resistance to induction 
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chemotherapy, increased risk for advanced disease, and poor 
prognosis. Mutation of the p53 gene is higher among patients 
exposed to tobacco or alcohol than among patients without 
exposure.29 
 
TIMELINE OF HEAD AND NECK CANCERS TREATMENT: 
 In the treatment of head and neck cancers, the first and only tool 
available to mankind was surgery. First of the modern surgery for cancer 
was carried out in United States for an ovarian tumor. This showed that 
surgical removal of the cancer was possible and it was possible to cure 
cancer. Later with the advances in cancer biology came the understanding 
about the cellular nature and origin of cancer. The discovery of X-Rays by 
William Roentgen in 1985 and the use of the first chemotherapy agents, 
nitrogen mustards in the 1940 have changed the face of oncology.  
  
The first of the head and neck cancer to be cured by Fractionated 
Radiotherapy was in 1928 and since then various modalities and 
combinations of treatment have been tried to increase the cure rate in these 
cancers. 
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TREATMENT OF HEAD AND NECK CANCERS: 
SURGERY:    
Surgery was the first modality to be used in the treatment of head 
and neck cancers. In the early years, surgery used to result in significant 
alteration of the body shape and also a significant loss of function too. 
However since then there has been significant improvement in surgical 
approaches and the development of plastic surgery has led to less morbid 
surgeries.  
All patients should be seen by a surgical oncologist before the start 
of the treatment. Surgery should aim to achieve surgical margins clear of 
the tumor.30 Positive margins are to be avoided as they have a poor 
prognosis and have a very high chance of local recurrence. Margins should 
be assessed by either frozen section or by formalin fixed samples of the 
tumor tissue. A clear margin is defined as a distance of more than 5mm 
from the tumor margin to the resected margin. A close margin is less than 5 
mm distance. A positive margin is defined as carcinoma in situ or invasive 
tumor at the resected margin.  
Surgery is the primary modality of choice in early stage cancers of 
oral cavity. Whereas in cancers of the hypopharynx and larynx they are 
indicated in the case of advanced stages, as early lesions are treated with 
the organ preservation intent. Lymph nodal dissection is also part of the 
surgical approach when it is carried out as a primary modality. Either 
14 
 
elective, selective or comprehensive neck node dissections are carried out 
on the basis of stage of the primary tumor and on the basis of the sub site 
involved. Tumors that have bilateral drainage will need bilateral neck 
dissection. The type of dissection can be summarized as follows: 
N0 – Selective dissection 
 Level I – III for Oral Cavity 
 Level II – IV for Oropharynx 
 Level II – IV for Hypopharynx and Larynx 
N1-2 - Comprehensive neck dissection / Selective Neck dissection 
N3 – Comprehensive neck dissection 
 Surgery also has role in recurrent tumors as a salvage modality. 
Patients who had surgery or radiation as a primary modality can undergo 
salvage surgery to achieve cure. They may also have a role in emergency 
settings such as bleeding due to erosion of blood vessels. Feeding vessels 
can be ligated to stop the bleeding as a palliative procedure.  
 
RADIOTHERAPY: 
 Radiotherapy has improved leaps and bounds since the first patient 
was cured with fractionated radiation in 1928. Radiation can used either 
alone or in concurrence with chemotherapy as a primary modality in 
curative intent. It is used alone in early stage cancers and along with 
chemotherapy in locally advanced diseases. It is also used in the 
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postoperative setting or adjuvant setting in locally advanced cancers after 
surgery as the primary modality. Post-operative RT is indicated in case of 
advanced T stage, multiple node positivity and perineural or 
lymphovascular invasion. Post-operative chemo radiation is indicated in 
the case of positive margins and extra capsular extension.22-25 
 Many a different fractionation schedules of RT has been 
experimented with for improving local control and for reducing normal 
tissue complications. No single fractionation schedule has been found to be 
the best for all tumors. Conventional fractionation is 2 Gy per day for 5 
days a week. Data are available suggesting that fractionation schedules 
delivering at least a 1000 cGy per week are needed for effective tumor 
control when RT alone is used as a treatment modality in early stage 
cancers to counteract the effects of tumor repopulation. Better 
understanding of the radiobiological concepts led to experimentation with 
altered fractionation schedules.31 These regimens are referred to as hyper 
fractionated and accelerated radiation. Hyper Fractionation exploits the 
differences in sensitivity to radiation between the tumor cells and normal 
adjacent tissues to achieve better tumor control and reduce the normal 
tissue complications. Accelerated Radiotherapy attempts to counteract the 
accelerated repopulation of tumor cells by reducing the duration of 
radiation by delivering continuous radiation. Pure acceleration is when the 
fractionation is similar to Conventional RT. Hybrid Acceleration is when 
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the fractionation parameters are changed to achieve the acceleration of 
radiation. The RTOG randomized trial 90-03 compared the relative 
efficacy of three altered fractionation regimens with Conventional RT 
delivering standard dose of 70 Gy in 35 fractions over 7 weeks32. The test 
radiation schedules were Hyper Fractionation (81.6 Gy in 68 fractions over 
7 weeks, with 1.2 Gy given twice daily), Split Course Accelerated 
Fractionation (67.2 Gy in 42 fractions of  1.6 Gy twice daily over 6 weeks, 
including a 2-week break), and a Concomitant Boost regimen (72 Gy in 42 
fractions over 6 weeks, with 1.8 Gy daily for the first 3.6 weeks and 1.8 Gy 
[large field] plus 1.5 Gy [boost field], 6 hours apart, for the last 2.4 weeks). 
Concomitant boost and hyper fractionation regimens yielded significantly 
higher loco regional control rates than those of standard fractionation. The 
split course accelerated regimen did not improve loco regional control rates 
over the standard fractionation regimen. The acute mucosal reactions were 
more severe in patients receiving the altered fractionation regimens, but 
there was no difference in the complication rates at 6, 12, 18, and 24 
months after therapy. 
 Total radiation dose needed for control of the tumour depends on 
size of the primary tumour, nodal involvement, fractionation schedule, use 
of concurrent chemotherapy. The gross primary and nodal tumour requires 
around 66 – 70 Gy in conventional RT. Elective nodal irradiation needs 
around 45 – 50 Gy.  
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High precision radiation therapy is possible with newer technologies 
such as 3D CRT and IMRT. 3D CRT is shaping the radiation beam with 
the use of multi leaf collimators (MLC) or beam modifiers to conform to 
shape of the target to deliver a highly conformal radiation. The technology 
of modulating the intensity of radiation within the treatment field to 
achieve better conformity is defined as Intensity Modulated Radiation 
Therapy (IMRT).  
Palliative RT is indicated in patients with poor performance status or 
in the case of very advanced diseases not eligible for curative treatment. 
Usually they are treated with hypo fractionated radiation. The standard 
hypo fractionation schedule in palliation is 300cGy per fraction to total of 
30Gy in 10 fractions over 2 weeks. 
 
CHEMOTHERAPY: 
Chemotherapy has been a part of the multimodality treatment of 
head and neck cancers for a long time. Various chemotherapeutic agents 
have been tried at various times. It has been tried in the neoadjuvant setting 
as an organ preservation approach in laryngeal cancers. The Veterans 
Affairs trial used chemotherapy in the neo adjuvant setting compared to 
concurrent chemo radiation to achieve organ preservation.  
 The publication of MACHNC meta-analysis made concurrent chemo 
radiation as the standard of care in locally advanced cancers.33-34 It was 
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established that the use of concurrent chemotherapy improved the overall 
survival by 8% at 5 years follow up. It was also established the Cisplatin is 
the chemotherapy of choice. Cisplatin can be used either in the full dose or 
weekly chemotherapy with equal benefits as long as the cumulative dose of 
Cisplatin reached 300 mg/m2 if used weekly.34 
 Chemotherapy also plays a very important role in incurable very 
advanced cancers and in metastatic cancers. It can be used as a palliative 
modality to contain the tumor proliferation. Various chemotherapeutic 
agents have been tried. No single agent has been identified as superior to 
others.    
 
TARGETED THERAPY:  
The first of the monoclonal antibody, Rituximab for Non-Hodgkin’s 
Lymphoma, was approved for clinical use in the year 1998. Since then 
there has been a burst of activity in this segment with multitude of agents 
being approved. Studies have shown that the EGFR receptor is over 
expressed in over 90% of the squamous cell carcinomas of the head and 
neck. This led to the speculation that they could be manipulated to control 
the tumor cells. This led to the development of EGFR inhibitors such as the 
monoclonal antibody Cetuximab and the inhibitors of downstream 
pathways like tyrosine kinase inhibitors such as erlotinib and geftinib. The 
landmark trial by Bonner et. al28 proved that addition of cetuximab 
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concurrently with radiotherapy in locally advanced head and neck cancers 
did result in a statistically significant improvement in loco regional control 
and in median overall survival. The EXTREME trial also showed that 
addition of cetuximab to the conventionally used doublet chemotherapy 
like Cisplatin and 5 FU regimens in metastatic and recurrent head and neck 
cancers resulted in an improvement in the overall survival.35 However the 
data regarding the use of the small molecules such as geftinib and erlotinib 
do not show any added benefit with its addition to the standard therapies in 
the recurrent or metastatic cancers. In addition COX-2 inhibitors, farnesyl 
inhibitors, and proteasome inhibitors are also being investigated in H&N.36-
37  
 
PREVENTION OF HEAD AND NECK CANCERS: 
 The concept of field cancerization has been in vogue for a long time. 
This concept hypothesizes that the entire upper aero digestive tract is 
subject to subcellular injury by exposure to carcinogens and so are 
susceptible to cancer formation. This implies that a person who develops 
and survives an upper aero digestive tract cancer is at an increased risk of 
another cancer in the region.38 They had an estimated 20% increased 
lifetime risk of formation of second primary tumor in the same field. This 
is due to accumulation of multiple genetic alterations over time. This forms 
the basis for chemoprevention.  
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 The premalignant conditions such as erythroplakia and leukoplakia 
are at increased risk of conversion into squamous cell carcinomas. But they 
have an unpredictable nature with most of them going in for spontaneous 
regression. They also regress after cessation of smoking. They were used 
as subjects for trials involving chemoprevention. The most widely tested 
chemo preventive agent is cis-retinoic acid.39-40 Although it showed 
promising results in early trials; subsequent trials did not live up to the 
promise. The Radiation Therapy Oncology Group (RTOG) completed a 
trial testing chemoprevention with 13-cis-retinoic acid in a multi-
institutional setting. Nearly 1400 patients with stage I or II cancer were 
accrued. Unfortunately, the RTOG trial was negative and did not show any 
benefit to low dose isotretinoin in the prevention of second primary 
cancers. So this area is still awaits further investigations for confirmation 
of the concept. Other chemo preventive agents being investigated are green 
tea extracts, curcumin extracts, soybeans etc. 
 
Other methods of prevention will include: 
1. Awareness regarding tobacco products6. Regulations controlling 
the sale of tobacco products. 
2. Abstinence from alcohol 
3. Awareness about sexual practices like oral sex resulting in HPV 
infection. 
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4. Good oral hygiene 
5. Good nutrient rich diet, fresh fruits and vegetables.  
 
RATIONALE FOR THE PRESENT STUDY: 
 As seen already, head and neck cancers are very common in our 
country. In our institution too they constitute the majority of the cancers 
registered in the OPD. And most of them present in the locally advanced 
stages. The presently available standards of the treatment with surgery and 
concurrent chemo radiation have a dismal performance in long term control 
with overall survival at 2 years hovering around the 50% mark and less 
than 20% surviving 5 years.41-43 Various modalities are being devised to 
overcome this. This is where the intensification of the treatment is 
considered. The previously used induction chemotherapy regimens are 
considered to be suboptimal now. The three drug regimens with the 
inclusion of a taxane44-45 and following the induction phase of treatment in 
the responding patients with concurrent chemo radiation as the loco 
regional treatment is being assessed as a form of intensification of 
treatment. The argument for induction chemotherapy before the loco 
regional treatment is that it results in reduction of the tumor load, thereby 
resulting in better loco regional control. Also it has been alleged that 
adjuvant chemotherapy has not any given benefit because the patient will 
not be able to tolerate the adjuvant therapy and also because the blood 
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supply to the local areas would have been altered. When the same is given 
in the neoadjuvant setting, the blood circulation in these areas is intact and 
will supposedly result in better results.  
 With these understandings, there has been a renewed interest in 
addressing locally advanced head and neck cancers with sequential 
therapy. So the present study justified in addressing this question.    
 
 
 
 
 
 
  
 
 
LITERATURE 
REVIEW 
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2. LITERATURE REVIEW 
 With results in single modality approach with either surgery or 
radiotherapy alone plateauing and no further advances being made in either 
of them alone, attention turned towards combined modality approaches. 
Radiotherapy following surgery was the standard approach in the case of 
locally advanced resectable head and neck cancers. Chemo radiation is the 
standard of care in unresectable locally advanced and neck cancers and 
also in resectable cases where organ preservation is the intent.  
 The Meta-Analysis of Chemotherapy on Head and Neck Cancer 
(MACH-NC) was probably the first report that definitively proved the 
benefit of adding chemotherapy to loco regional treatment like 
radiotherapy in any setting. A 12% reduction in the risk of death was the 
benefit that could be obtained because of adding chemotherapy in patient 
with squamous cell carcinoma of the head and neck. This translated to 
absolute increase in the 5 years survival of these patients by 4%.  A more 
recent update of the meta-analysis has shown that this benefit is even 
higher. The reduction in the risk of death is increased to 19% and the 5-
year survival increased to 8% improvement in comparison with treatment 
with RT alone. Further analysis of the study brought out clearly the fact 
that concurrent chemotherapy was the reason behind all this benefit and not 
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the addition of chemotherapy in other settings like neoadjuvant and 
adjuvant chemotherapy.33-34  
 Even with these advances in therapeutics, it has been observed that 
around 50 – 60% of the locally advanced cancers will recur within first 2 
years of follow up. Literature also notes that there will be around 15 – 20% 
of distant metastasis. So, multiple permutations of the different modalities 
have been tried for achievement of maximum benefit. This resulted in the 
incorporation of chemotherapy in various forms along with RT in head and 
neck cancers. One of these was inclusion of chemotherapy in the 
neoadjuvant setting aiming for better loco regional control and also for 
organ preservation. It has long been known that platinum is the most 
effective agent in head and neck cancer. 
The radiobiological concept behind any neoadjuvant therapy is that 
it will result in a reduction of the tumour load and result in lesser load for 
the loco regional treatment. It is well known that the cells derive nutrition 
and oxygen from the nearby blood vessels by way of diffusion. This 
diffusion is limited by the distance from the blood vessel by only up to the 
first 100 microns. As the load of the tumour cells increase, the cells in the 
periphery have easy and good access to the vessels and are very well 
oxygenated.  Whereas the centre of the tumour is hypo oxygenated and has 
a necrotic area46-47. This will result in a less than optimal response to the 
fractionated radiation. There is an intermediate zone between these two 
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areas having intermediate oxygenation. It has been found out that any 
tumour exceeding a size of around 180 microns will have variable 
oxygenated areas and a necrotic centre.  
 
Fig: 1 – Extent of oxygenation in a tumour 
   
Oxygen is very important for the production of free radicals which 
sets up the action of radiation in killing the tumour cells. But oxygen gets 
depleted rapidly as it diffuses from the vessels to surrounding tissue. This 
is about 70 microns from the arterial end of the tumour and it is less than 
that from the venous end. This is also the logic behind fractionated 
radiation. With each fraction, the cells in the periphery are killed and the 
cells in the intermediate zone gain better access to the oxygen supply and 
are sensitive to the next fraction of radiation. So it also implies that when 
the size of the tumour is small at the start of the radiation, it will result in 
better control of the tumour as it will have less hypo oxygenated areas. 
Similarly when induction chemotherapy is given it results in a gross 
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reduction of the tumour volume and the hypo oxygenated areas become 
well oxygenated and so becomes more sensitive to radiation.48  
          
 
Fig: 2 -Oxygen diffusion 
  
 VETERANS AFFAIRS TRIAL:  
The Department of Veterans Affairs laryngeal study group 
conducted a phase III randomized study in locally advanced squamous cell 
carcinomas of the larynx to compare the results of induction chemotherapy 
followed by radiation with the standard management of laryngectomy 
followed by postoperative radiation.49 Three hundred and thirty two 
patients were randomly assigned to the two arms. The induction 
chemotherapy arm received two cycles of Cisplatin and 5 FU. They were 
assessed at the end of the two cycles. Those who had a response received a 
third cycle of induction chemo followed by definitive radiotherapy of 66 – 
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70 Gy. The patients who had no response to the induction or those who had 
a recurrent tumour after the treatment was over underwent salvage surgery.  
 After a median follow up for 33 months, the estimated 2 year 
survival was equal in the two groups. However the pattern of recurrence 
differed in the two treatment groups. The local recurrences were more in 
the larynx preservation arm (P= 0.0005) and the distant metastasis was less 
in the chemotherapy arm (P=0.016). Larynx was preserved in around 64% 
of the recruited patient. This showed that there is a role for chemotherapy 
in advanced laryngeal cancer. The strategy involving induction 
chemotherapy followed by definitive radiotherapy can be effective in the 
preservation of functional larynx in the case of locally advanced laryngeal 
cancers. The authors concluded that in view of the high rate of local 
recurrences in the case of chemotherapy arm, more effective local therapy 
is needed to achieve larynx preservation.  
 
THE STUDIO TRIAL:   
The Gruppo di Studio sui Tumori della Testa e del Collo conducted a 
phase III induction trial evaluating the role of PF induction chemo before 
the loco regional management50. The 237 patients were randomized to two 
arms. Arm A received Cisplatin (100mg/m2 On D1) and 5 FU (1000mg/m2 
per day, continuous infusion from D1to 5), every 21 days for 4 cycles 
before they were taken up for loco regional treatment by radiotherapy with 
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or without surgery (n=118). Arm B received the loco regional treatment 
alone (n=119). The results of the study showed that in case of the upfront 
operable patients the addition of the chemotherapy did not add significantly 
to the overall survival. However, PF arm did improve the overall survival 
significantly at both the 5 year and 10 year follow up of the patients in the 
case of inoperable patients51. There was a reduction in loco regional 
recurrences and also the distant metastasis.  
 
GETTEC OROPHARYNX TRIAL:  
 In a trial conducted by the Groupe d'Etude des Tumeurs de la Tête et 
du Cou52, 318 patients of locally advanced oropharyngeal cancer were 
randomized to two arms. Patients in Arm A received neoadjuvant 
chemotherapy consisting of Cisplatin (100 mg per m2) on D1 and 5 FU 
(1,000 mg per m2 per day) for 5 days continuous infusion, every 21 days 
for 3 cycles. Chemotherapy was followed after 2- 3 weeks by radiotherapy 
with or without prior surgery. Arm B received upfront loco regional 
treatment. The study included primary oropharyngeal cancers except those 
involving the posterior wall and the anterior surface of the epiglottis. They 
included 48.1% of stage III cancers and 26.1% of stage IV cancers. The 
response rate to the induction chemo arm was 56%. The induction 
chemotherapy arm had a clinically significant benefit in the follow up 
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analysis. The median OS time was significantly better (5.1 yrs. versus 3.3 
yrs.; p = .03).  
 
RTOG 91-11: 
` RTOG conducted a phase III trial for examining induction 
chemotherapy in larynx preservation in RTOG 91-1153-54. The trial 
randomized 547 patients of stage III & IV cancers of the larynx to three 
arms. Arm A randomized patients to fractionated RT,  arm B to concurrent 
chemo radiation with concurrent Cisplatin and arm C to neoadjuvant 
chemotherapy with Cisplatin and 5 FU followed by chemo radiation or 
surgery. The trial included 64.2% of stage III cancers and the remaining 
were stage IV cancers. The loco regional control was superior in the chemo 
radiation arm compared to the induction arm (68.8% vs. 54.9%, P < 
0.0018). The results of the trial with a median follow up of 6.9 years 
showed that laryngectomy free survival (LFS) was significantly superior in 
both the induction and chemo radiation arm compared to the radiotherapy 
alone arm. But the LFS was similar in both the induction and CRT arms. 
The end points of laryngeal preservation and loco regional control rate was 
significantly superior in the chemo radiation arm. The disease free survival 
was similar in CRT and induction chemo arm but the overall survival was 
similar in both arms during the first 5 years of follow up. After that it 
favoured the induction chemo arm.  
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MACH-NC META-ANALYSIS: 
The meta analysis of the combined modality treatments in 
MACHNC showed that inclusion of chemotherapy in the management of 
the head and neck cancers significantly improved the absolute benefit by 
4% at 5 years from 32% to 36%. The chemotherapy were used in 3 
different ways  
1. Neoadjuvant chemotherapy 
2. Concurrent chemotherapy 
3. Adjuvant chemotherapy 
 
There was a significant interaction with respect to the timing of the 
chemotherapy in relation to the radiation treatment. In the subset analysis, 
it was shown the most benefit was derived out of the use of concurrent 
chemotherapy (8%, p= 0.0001). The other modalities like adjuvant and the 
neoadjuvant chemotherapy contributed only a non-significant 1% and 2% 
absolute benefit respectively33-34.  
 
So why give induction chemotherapy another chance in the 
treatment of locally advanced head and neck cancers? 
 Previous studies included suboptimal chemotherapy regimens. 
Now we know that the optimal chemotherapy should include a 
platinum agent. 
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 Newer triple agent chemotherapy with the inclusion of taxane. 
Various phase II trials have shown that the three drug regimen 
with the inclusion of a taxane to Cisplatin and 5 FU is 
superior. 
 Previous neoadjuvant chemo studies have mostly followed the 
chemotherapy phase with a single modality of loco regional 
treatment with either surgery or radiation. This was felt to be 
the reason for the failure of the induction regimens. So newer 
trials with chemotherapy followed by chemo radiation are 
being carried out. 
 
The initial trials of sequential therapy tried out variety of 
combinations in the induction phase and in the concurrent chemo radiation 
phase. The University of Pennsylvania carried out a phase II trial with high 
dose paclitaxel and carboplatin in the induction regimen followed by 
chemo radiotherapy55. The chemotherapy during radiation was low dose 
paclitaxel. This trial was carried out in oropharyngeal cancers. With a short 
follow up for 31 months, the response rates of the trial were 91% following 
the entire course of the treatment.  
Another induction regimen tried out on a weekly basis was 
Paclitaxel, Carboplatin and Ifosfamide56. This was delivered as an 
32 
 
outpatient treatment. But the results of this trial showed a very high 
response rates but longer follow up is needed to confirm this. 
Other newer agents in the induction regimen are taxanes, Paclitaxel 
and Docetaxel. Several phase II trials were conducted to find put the 
efficacy of adding paclitaxel. The Spanish Head and Neck Cancer group, 
Hitt et al carried out two phase II trials to evaluate the feasibility of adding 
Paclitaxel to Cisplatin and 5 FU57, 58. The results are given below: 
 
 
 
GORTEC:  
This phase III trial was carried out by the French Head and Neck 
Cancer Study Group as an organ preservation trial in larynx to test the 
efficacy of adding docetaxel in the induction regimen along with Cisplatin 
and 5 FU and was compared with the standard chemotherapy regimen of 
Cisplatin and 5 FU alone59. The induction chemotherapy was delivered in 
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the following doses, Docetaxel (75mg/m2 on Day1), Cisplatin (75mg/m2 on 
Day 1) and 5 FU (750 mg/m2 as a continuous 24 hour infusion from Days 
1-5). Three cycles were delivered every 21 days. 220 patients were 
randomized to the two study arms and analysed. The overall response rate 
(T and N) was 82.8% in the TPF vs. 60.8% (p = 0.0013). 60.6% of patients 
achieved a complete endoscopic response in the TPF arm vs. 46.7% in the 
PF arm. In advanced laryngeal and hypo pharyngeal cancer, TPF 
demonstrated significantly superior overall response rate compared to the 
PF regimen. The TPF is better tolerated and preliminary results suggest 
that laryngeal preservation could be achieved for a higher proportion of 
patients. This trial showed that addition of docetaxel did result in an 
improved laryngectomy free survival. (P = 0.036) This implies that there 
was an improvement in the loco regional control. 
 
TAX 323:60  
This study accrued a total of 358 patients of head and neck cancer. It 
randomized 177 patients to the TPF group and the remaining 181 patients 
were allotted to the PF group. The patients in the PF group received 4 
cycles of chemotherapy with Cisplatin (100 mg/m2 Day 1) and 5 FU (1000 
mg/m2 continuous infusion 24 hours from Day 1- 5) alone every three 
weeks. The patients in the TPF group received three drug regimen with the 
addition of Docetaxel (75 mg/m2 on Day1) along with Cisplatin (75mg/m2 
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day1) and 5 FU (750 mg/m2 continuous 24 hour infusion from Day 1 -5). 
This was administered for 3 cycles every 3 weeks.  The induction phase 
was followed by radiotherapy within 4-7 weeks unless they had 
progressive disease at the end of the induction phase. Radiation was 
delivered in either conventional fractionation or accelerated or hyper 
fractionated regimens. The total dose in conventional fractionation was 66 
to 70 Gy, in accelerated regimen was 70 Gy and in the hyper fractionated 
radiation was 74 Gy. The choice of the radiotherapy was by institutional 
policy, which was fixed for the institution before the start of the study. The 
primary end point of the study was progression free survival and the 
secondary end points were overall survival, time to treatment failure etc. 
The analysis of the results of the trial showed that the addition of docetaxel 
resulted in a significant improvement in progression free survival with 11.0 
months in the TPF group compared to 8.2 months in the PF group 
(P=0.007). The secondary end point of median overall survival was 18.8 
months in the TPF group compared to the 14.5 months in the PF group. 
This amounted to a significant decrease in death risk by 27% (p value = 
.02). However, as expected the grade 3 or 4 adverse events were higher in 
the TPF arm.  
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TAX 324: 61 
The TAX 324 study randomly assigned 501 patients with stage III 
and IV head and neck cancers all of whom had primary tumours which 
were unresectable or who were candidates for organ preservation, to 3 
cycles of docetaxel (75mg/m2 on Day 1), Cisplatin (100 mg/m2 on Day 1) 
and 5 FU (1000 mg/m2 on continuous 24 hour infusion days 1-4) or 3 
cycles of Cisplatin (100 mg/m2 on Day1) and 5 FU (1000 mg/ m2 Day 1- 5) 
alone followed by concurrent chemo radiation with weekly carboplatin. 
The induction chemotherapy was given as 3 weekly cycles. All the patients 
received chemo radiotherapy 3-8 weeks following the completion of the 
entire induction chemotherapy. The radiation was delivered in 
conventional fractionation schedule of 2 Gy per day for 5 days a week to a 
total dose of 70 to 74 Gy. Weekly carboplatin was delivered at a dose of 
AUC 1.5. The primary endpoint of the study was overall survival. The 
results of this study at the end of 2 years showed a significantly more 
number of patients in the TPF arm surviving with a median survival of 71 
months. Whereas it was only 30 months in the PF arm (P=0.0006). The 
loco regional control was also significantly better in the TPF arm compared 
to the PF arm (p=0.04). It reduced the incidence of loco regional recurrence 
by 27%. But the incidence of distant failure was similar in the two groups. 
Although the organ preservation was not the aimed at end point in this 
study a subset analysis of the laryngeal and hypo pharyngeal cancers did 
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show a better response with three drugs for PFS which can be taken as a 
surrogate for LFS (p =.032)  
 
With the results of these studies it was concluded that if induction 
was to be used, TPF was the standard regimen. However the question still 
remained whether this sequential therapy with induction chemotherapy 
followed by loco regional treatment was superior to that upfront chemo 
radiation. Various studies were carried out to determine this.  
 
HITT et al:  
The Spanish Head and Neck Cancer Cooperative group62 
randomized the stage III or IV squamous cell carcinomas of the oral cavity, 
oropharynx, hypopharynx, larynx to either 3 cycles CDDP (100 mg/m2 on 
Day 1), 5FU (1000 mg/m2 on Day 1-5) or 3cycles of TPF, Docetaxel (75 
mg/m2 Day 1), Cisplatin (75mg/m2 on Day1), 5FU 750mg/m2 Days 1-5 as 
24 hour continuous infusion) followed by chemo radiation or to chemo 
radiation alone. The chemo radiation was delivered as once daily fractions 
of 2 Gy to a total dose of 66-70 Gy along with a full dose of Cisplatin 100 
mg/m2 on Days 1, 22, 43. The primary endpoint of the study was the time 
to treatment failure. The secondary end points were time to progression, 
loco regional control, overall survival and safety assessment. Both the time 
to progression (p=0.056) and the time to treatment failure (p<0.0001) were 
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significantly improved in the induction arms compared to the chemo 
radiation alone arm. The secondary end point of local control rate was 
significantly more in the induction arms (61.5% vs. 44.5%, p= 0.002) 
 
DeCIDE: (DOCETAXEL BASED CHEMOTHERAPY PLUS OR 
MINUS INDUCTION CHEMOTHERAPY TO DECREASE EVENTS 
IN HEAD AND NECK CANCER) 63 
  
Patients of locally advanced head and neck cancers were randomized 
to either induction chemotherapy arm or upfront chemo radiation arm. The 
induction had two 21 day cycles of induction chemo with Docetaxel, 
Cisplatin and 5 FU followed by chemo radiation. The chemo radiation was 
delivered with twice daily radiation (150cGy BID) and five 14 day cycles 
of docetaxel (25mg/m2 for 5 days), 5 FU (600mg/m2 for 5 days) and 
hydroxyurea (500mg BID) followed by a 9 day break. The goal of this 
study was to find out any difference in overall survival. The secondary end 
points of the study were distant failure free survival, failure pattern, 
progression free survival and quality of life assessment. The study 
recruited 280 patients, much less than the planned 400 patient accrual. 
With a minimum follow up of 2 years, overall survival, distant failure free 
survival, recurrence free survival was not different between the two arms. 
Although high overall survival rates were seen in both arms, the reasons 
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why the significant decrease in the distant failure in the induction arm did 
not translate into a better overall survival.   
 
PARADIGM: 64 
This is a multicenter phase III trial comparing sequential therapy and 
upfront chemo radiation. The study recruited 145 of the planned 300 
patients. The induction chemo regimen used in this trial was 3 cycles of 
docetaxel, 5FU and Cisplatin followed by chemo radiation with either 
weekly carboplatin and conventional radiation or weekly docetaxel and 
accelerated radiotherapy. The upfront chemo radiation arm was treated 
with 2 cycles of full dose Cisplatin on week 1 and week 4 along with 
accelerated boost RT. The primary end point for this study was 3 year 
overall survival. The secondary end points were many and can be listed as 
follows:   
• 2, 3 and 5 yr. PFS  
• 5 year survival  
• CR 
• Tumor site specific survival  
• Organ preservation  
• Toxicity profile  
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• Quality of life 
The three years overall survival and the three year progression free survival 
were not statistically different in the two arms.  
 The two studies which had compared the sequential therapy 
approach with TPF induction followed by concurrent chemo radiation with 
upfront chemo radiation, DeCIDE and PARADIGM, had failed showed to 
show any advantage for the sequential approach. But the question of 
sequential therapy in head and neck cancers is far from settled, as these 
studies had some serious flaws in their design which limits the significance 
of their outcome. Both studies did not complete the planned accrual of 
patients and in fact they were way short of the target. So this brings into 
question the statistical power of the studies to show a significance of one 
over the other. Also the optimal number of cycles of induction 
chemotherapy is not known. Most of the trials have delivered at least three 
cycles of chemotherapy. But the DeCIDE trial delivered only two cycles of 
induction chemotherapy. Also both the trials delivered sub optimal loco 
regional treatment. The chemo radiation schedules followed were not the 
ideal. We know for a fact from the MACH NC report that Cisplatin is the 
drug of choice for concurrent CRT. But both the trials had excluded 
Cisplatin as the concurrent chemotherapy. So taking into account all these 
facts, the question of whether sequential therapy is better than chemo 
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radiation alone is still to be answered. Further trials are on-going to answer 
this question. 
 
GSTTC Trial: 
 In this phase II study conducted by the Gruppo di Studio della Testa 
e del Collo, 65 101 patients with unresectable locally advanced Head and 
Neck Cancer patients were randomized to receive either Concurrent chemo 
radiation with Cisplatin 20 mg/m2 on days 1–4 and 5-FU 800 mg/m2/day 
as a 96-h continuous infusion during weeks 1 and 6 of RT or three cycles 
of TPF (Docetaxel 75 mg/m2 and Cisplatin 80 mg/m2 on day 1 and 5-FU 
800 mg/m2/day as a 96-h infusion, every 3 weeks) followed by the same 
CRT regimen. The primary end point assessed was complete response 
rates. This was higher with the TPF arm (50% Versus 21.2%, P = 0.004). 
The secondary end points of median PFS and OS were superior in the TPF 
induction arm.  
  
 To sum up, the benefits of induction chemotherapy will include the 
reduction of load of the tumour before the start of the loco regional 
treatment which theoretically should increase the sensitivity of the loco 
regional treatment66-67. This should directly result in a better loco regional 
control rates. When irradiation is used it results in wider irradiation 
margins. But there are certain theoretical disadvantages which have to be 
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kept in mind and these have to be addressed in the future. One is the 
purported delay in the start of the primary modality of treatment potentially 
resulting in reduced response rates. Also there is the possibility of 
neoadjuvant chemotherapy resulting in selection of resistant clones of 
tumour which results in sub optimal response rates. Also there is a chance 
that the patient may default for primary modality of treatment with the 
response achieved by the neoadjuvant chemotherapy in alleviating the 
symptoms. There is also a chance that the patient may not be able to 
tolerate the full course of loco regional treatment and complete it within the 
stipulated time because of the toxicities of the neoadjuvant chemotherapy.  
 The present study is justified because despite decades of research 
and trials in locally advanced head and neck cancers with various 
modifications in radiation fractionation, inclusion of chemotherapy in the 
loco regional treatment, the use of targeted therapies, the response rates 
and overall survival is still dismal and has not improved by much. The 
correct combination of the all the modalities to achieve the best response is 
not yet known.    
 
 
 
  
 
AIM & OBJECTIVES 
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3. AIMS & OBJECTIVES 
 
AIM:  
The aim of the present study was to evaluate the sequential therapy 
in locally advanced head and neck cancers with three cycles of induction 
chemotherapy with Paclitaxel, Cisplatin and 5 FU followed by concurrent 
chemo radiation with conventional irradiation along with weekly Cisplatin. 
  
PRIMARY OBJECTIVE:  
 To assess the immediate loco regional response rates of locally 
advanced squamous cell carcinomas of the head and neck treated with 
sequential therapy, to be assessed after induction chemotherapy and after 
loco regional therapy.  
            
SECONDARY OBJECTIVE:   
To assess acute toxicity patterns of the treatment regimen, to be 
assessed during the induction phase and during the chemo radiation phase 
of the treatment. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
METHODOLOGY 
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4. MATERIALS AND METHODS 
STUDY DESIGN:  
The present study was a Single Arm Prospective Study of 
previously untreated patients receiving sequential therapy for locally 
advanced head and neck cancer.  
The study got approval from the Ethics Committee of the institution 
prior to opening for accrual and all patients signed an informed consent 
form in Tamil prior to participating in the study.  
 
SAMPLE SIZE: 
30 consecutive patients of locally advanced head and neck cancers 
attending the Out-Patient Department at our Institute who met the inclusion 
criteria were enrolled in the study. 
 Eligible patients had to have histologically or cytologically proven 
squamous cell carcinoma in the head and neck region in the locally 
advanced stage by TNM staging.  
They had to be eligible for curative treatment on the basis of the 
extent of their disease, medical comorbidities, distant metastasis and/or 
combination of these factors.  
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INCLUSION CRITERIA:   
• Biopsy proven squamous cell carcinoma of the head and neck. 
• Primary tumor sites eligible: oral cavity, oropharynx, hypopharynx, 
larynx.  
• Age >18years to < 70 years. 
• Stage III or IV disease without evidence of distant metastases.  
• ECOG Performance Status 0 – 2. 
  
 
EXCLUSION CRITERIA:  
• Patient not consenting to chemotherapy at any point in the treatment. 
• Previously received treatment for any other malignancy. 
• Tumors of nasal cavity, paranasal sinuses and nasopharynx. 
• Non Squamous Histopathology. 
• Inadequate hepatic and renal functions. 
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PRE-TREATMENT WORK UP AND GENERAL MEASURES: 
1. Elucidate the history of the symptoms.  
2. Visual examination and palpation of oral cavity and proximal 
oropharynx. 
3. Neck examination for regional lymph nodes involvement. 
4. Thorough clinical examination of the entire upper aero digestive 
tract to rule out a second primary. IDL and VDL scopy, direct nasal 
examination, anterior and posterior rhinoscopy. 
5. Biopsy from tumor or FNAC from neck node.  
6. Complete blood count, renal and liver function tests before every 
cycle of induction chemotherapy. 
7. CT scan Neck (From Base of Skull to Root of Neck) – Plain and 
Contrast before start of treatment and after completion of induction 
chemotherapy and at first follow up. 
8. Chest X-Ray – PA view. 
9. X-Ray Mandible to rule out cortical bone involvement. 
10. Weekly blood counts and renal function tests during radiotherapy.   
11. Cardiology fitness for chemotherapy. 
12. Nasogastric intubation as required before starting treatment. 
13. Dental prophylaxis by extraction, filling and scaling. 
46 
 
STUDY PROTOCOL: 
INDUCTION PHASE:   
All patients were treated with three cycles of induction 
chemotherapy given every 21 days over a period of three days on an in-
patient basis.  
The schedule followed for induction chemotherapy regimen 
delivered was: 
Premedication given half an hour before every chemotherapy: 
• Inj. Ondansetron 8 mg IV. 
• Inj. Dexamethasone 8mg IV 12 hours and 6 hours before 
chemotherapy and half an hour before chemotherapy. 
• Inj. Ranitidine 50 mg IV. 
• Inj. Chlorpheniramine 1 vial.  
The chemotherapy per se was delivered in the following schedule 
every 21 days: 
• Inj. Paclitaxel 175mg/m2 D1 as a 3 hour infusion.  
• Inj. Cisplatin 100mg/m2 split in three days D1-D3 as a three 
hour infusion.  
• Inj. 5-FU 750mg/m2 D1-D3 as bolus injection. 
47 
 
All the patients were assessed on Day 8 -10 of every cycle with 
complete blood count for myelosuppression. Patients with suppression 
were kept under close observation. No intervention was allowed. If the 
patient had febrile neutropenia/Grade 4 neutropenia, they were treated with 
G-CSF 300mcg s.c. on days 1-3. All other grades of myelosuppression 
were kept under observation and assessed before the start of the next 
chemotherapy. If myelosuppression still persisted they were treated with 
G-CSF with the above mentioned schedule.  
All patients who needed secondary prophylaxis in previous cycles as 
per the above mentioned protocol were given primary prophylaxis with G-
CSF in the subsequent cycles of chemotherapy during Days 8-10 of the 
cycle.  
ASSESSMENT AFTER INDUCTION:  
Patients were reassessed both clinically with all the initial 
investigation which were abnormal to begin with and with an imaging, CT 
or MRI Neck from Base of Skull to Root of Neck after completion of the 
entire course of the induction chemotherapy.  
CONCURRENT CHEMORADIATION: 
The patients with a response to chemotherapy were then taken up for 
Radical Concurrent Chemo Radiation.  
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Radiotherapy Technique: 
           The radiation was delivered in conventional fractionation with a 
Theratron Phoenix Tele Cobalt – 60 machine. The radiation was delivered 
on an out-patient basis for local patients or on an in-patient basis for 
patients from other localities. All the patients were delivered the weekly 
chemotherapy on an in-patient basis every week. 
Dose per fraction:  2 Gy per fraction over 5 days a week.  
Total dose:  66Gy to the gross tumor and positive nodes and 50 Gy 
to the elective nodes. 
Radiotherapy was delivered by opposing lateral fields in a Theratron 
Phoenix Tele-Cobalt machine in 200cGy per fraction for 5 days a week. 
Patients are given a break on Saturday and Sunday.  
Appropriate shielding of the spinal cord was done after the tolerance 
dose of spinal cord was reached at 40 Gy. 
In view of the intense regimen of induction phase chemotherapy 
which is being followed up with concurrent chemo radiation, all patients 
were started on prophylactic measures to prevent development of mucositis 
and infection during radiotherapy. The measures taken were: 
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1. Soda Bicarbonate Solution mouthwash at least 4 times a day, 
before and after food and at bed. After one week on radiation, 
patients were instructed to rinse every 3 – 4 hours. 
2. Alcohol free antibacterial mouth wash. 
3. Daily brushing of teeth with soft baby toothbrush. 
4. Inj. Dexamethasone 8 mg IV BD was started after 10 fractions of 
RT and was continued till the end of radiotherapy. Then it was 
tapered and stopped after the end of RT. 
Weekly Chemotherapy:  The patients also received concurrent 
chemotherapy of weekly Cisplatin at a dose of 40mg/m2 after assessing the 
renal parameters and the hemoglobin levels.   
Premedication were given half an hour before every weekly 
chemotherapy: 
• Inj. Ondansetron 8 mg IV. 
• Inj. Dexamethasone 8mg IV. 
• Inj. Ranitidine 50 mg IV. 
• Inj. Chlorpheniramine 1 vial.  
The entire treatment schedule was to be completed in 6.3 weeks. 
Patients with progressive disease after induction chemotherapy were 
taken up for palliative chemotherapy/radiotherapy.  
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Fig. 3- Protocol Scheme 
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TOXICITY: 
Toxicity in the present study was graded using Common Toxicity 
Criteria Version 4 and RTOG Acute Radiation Morbidity Scoring Criteria. 
         All blood parameters like complete blood count and the basic 
metabolic panel were assessed before the start of every cycle of induction 
chemotherapy and during the nadir period, 8th to 12th day of every cycle. In 
the case of WBC less than 1000/µl or platelets less than 50,000/µl for a 
period longer than 5 days, drug doses were reduced by 10% in the next 
cycle.   
Complete blood count and biochemistry were performed on a 
weekly basis during chemo radiotherapy.  In the case of any severe grade 3 
or 4 toxicities, radiation therapy was interrupted until recovery and 
appropriate treatment instituted as discussed in following sections. 
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TABLE - 1: CTCAE Version 4 for Nausea & Diarrhea: 
 
GRADE 
 
NAUSEA 
 
1 
 
Loss of appetite without alteration in eating habits. 
 
2 
 
Oral intake decreased without significant weight loss, 
dehydration or malnutrition. 
 
3 
 
Inadequate oral caloric or fluid intake; tube feeding, TPN, or 
hospitalization indicated 
  
DIARRHOEA 
 
1 
 
Increase of 2-3 stools/day. 
 
2 
 
Increase of 4-6 stools/day, nocturnal stools or moderate cramps. 
 
3 
 
Increase of 7-9 stools/day or incontinence, or severe cramping. 
 
4 
 
Increase of >10 stools/day or grossly bloody diarrhea, or need for 
parenteral support. 
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TABLE - 2: RTOG Acute Morbidity Scoring Criteria 
 
Grade 
 
0 
 
1 
 
2 
 
3 
 
4 
 
MUCOSI
TIS 
 
No 
Change 
 
Injection / 
Mild pain 
not requiring 
analgesic 
 
Patchy 
mucositis 
Moderate 
pain needs 
analgesia 
 
Confluent 
Mucositis 
Severe 
pain, needs 
morphine 
 
Ulceration, 
hemorrhage 
and Necrosis 
 
DERMAT
ITIS 
 
No 
Change 
 
Follicular, 
faint, dull 
erythema/ 
epilation/ 
desquamatio
n 
 
Tender, 
bright patchy 
moist 
desquamation 
 
Confluent 
moist 
desquamati
on 
 
Ulceration, 
hemorrhage 
and Necrosis 
 
SALIVAR
Y GLAND 
 
No 
Change 
 
Mild dryness 
/ Altered 
taste 
 
Moderate to 
complete 
dryness 
 
--------- 
 
Necrosis 
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PHARYNX 
 
No Change 
 
Mild 
dysphagia 
requiring 
analgesics 
 
Moderate 
dysphagia 
requires 
narcotics. 
Liquid diet 
 
Requires 
IV fluids 
or NG 
tube 
 
Ulceration, 
perforation 
and fistula 
 
LARYNX 
 
No Change 
 
Mild 
Hoarseness, 
Cough not 
needing 
antitussive 
 
Persistent 
hoarseness, 
Cough 
requiring 
antitussive 
 
Whispered 
speech, 
throat pain 
requiring 
narcotics 
 
Dyspnea/ 
stridor, 
hemoptysis 
with 
tracheostomy 
 
WBC 
(X1000) 
 
>= 4.0 
 
3 – 4 
 
2 – 3 
 
1 – 2 
 
<1 
 
PLATELE
T (X1000) 
 
>=100 
 
75 – 100 
 
50 – 75 
 
25 – 50 
 
< 25 or 
spontaneous 
bleeding 
 
HEMOGL
OBIN 
(gm %) 
 
>11 
 
9.5 – 11 
 
7.5 – 9.5 
 
5.0 – 7.5 
 
------- 
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RESPONSE EVALUATION: 
          Tumor response will be evaluated 4-6 weeks after end of course with 
CT Neck from base of skull to root of neck and clinical examination. The 
criteria used were RECIST 1.1 Criteria. 
 Complete Response (CR): Disappearance of all target lesions. 
 Partial Response (PR): At least a 30% decrease in the sum of the LD 
of target lesions, taking as reference the baseline sum LD. 
 Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor 
sufficient increase to qualify for PD, taking as reference the smallest 
sum LD since the treatment started. 
 Progressive Disease (PD): At least a 20% increase in the sum of the 
LD of target lesions, taking as reference the smallest sum LD recorded 
since the treatment started or the appearance of one or more new 
lesions. 
 
FOLLOW UP PROCEDURE: 
           Patients were assessed for disease status 1 month after the end of 
treatment and every month thereafter. During follow up, a thorough 
history, physical examination and complete clinical examination were 
done.  
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ANALYSIS: 
Patients were analyzed for local response rate after the induction 
chemotherapy and the end of the concurrent chemo radiation. The toxicity 
of treatment and the factors affecting the treatment response were 
analyzed.  
The probability test used to identify p value is FISHER’S EXACT 
PROBABILITY TEST. 
 
 
 
 
  
RESULTS AND 
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5. RESULTS AND ANALYSIS 
 
 The present study enrolled a total of 30 patients with histologically 
proven locally advanced squamous cell carcinoma of the head and neck 
region. The method of selection was enrolling 30 continuous patients at the 
OPD who met the eligibility criteria of the study as laid out previously. 
 All the patients underwent baseline investigations and work up 
before the commencement of the treatment. 
SEX: 
 Among the 30 patients enrolled for the study majority of them were 
males accounting for 27 of the total. This skewed selection towards the 
male gender is probably due to the higher incidence of head and neck 
cancers in males, as they are more commonly exposed to the carcinogens 
than the women.  
AGE: 
 The age group eligible for the study was from 18 to 70 years of age. 
The age of the patients ranged from 24 to 69 years. The median age of the 
patients enrolled in the study was 50 years. Age distribution analysis of the 
sample showed that, majority of the patients were in the 36 to 64 year 
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group. However all the patients had an ECOG performance status either 1 
or 2. 
SITE DISTRIBUTION: 
 The site wise distribution of the cancers in the enrolled patients 
when analyzed, they were almost equally distributed. 
1. Oral Cavity – 9 (29.97%) 
2. Oropharynx – 9 (29.97%) 
3. Hypopharynx - 9 (29.97%) 
4. Larynx – 3 (9.99%) 
SUBSITE INVOLVEMENT: 
The patients with oral cavity cancers had involvement of the anterior 
two thirds of the tongue in 4 patients and 1 patient had involvement of the 
floor the mouth. In the patients with cancer of the oropharynx, 3 had 
involvement of the tonsillar fossa and the soft palate. There was 
involvement of the posterior third of the tongue in the other 6 patients.  
The hypo pharyngeal cancers were mostly pyriform fossa cancers 
with only two of them having post cricoid cancers. 
 
 
Graph 1: Sex Distribution 
 
 
 
 
Graph 2: Age Distribution 
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Graph 7: Differentiation 
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STAGE GROUPING: 
 The patients had an almost equal representation of the AJCC stage 
grouping with 16 patients in the Stage III (53.28%) and 14 patients in the 
Stage IV (46.62%). 
 
TNM STAGING: 
 The TNM staging of the patients showed majority of the patients 
being in the T4 stage (n=16, 53.28%) and the N staging most commonly 
seen was N2 (n=18, 59.94%). 
There were 7 cases of N3 disease included in the study. The majority 
of the patients with N3 disease were hypo pharyngeal cancers accounting 
for 4 patients, with oropharynx following next with 2 patients. The 
remaining one was oral cavity.   
HISTOLOGY: 
Majority of the study population had histology which was 
moderately differentiated accounting for 63.27% (n=19 patients). They 
were distributed among the sub sites, with oropharynx being the majority 
having 7 cases. The poorly differentiated carcinomas were commonly seen 
in the hypo pharyngeal cancers. 
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Table 3: Age distribution 
Age No of Patients Percentage 
<35 3 9.99% 
35 – 49 13 43.29% 
50 – 64 13 43.29% 
65 – 70 1 3.33% 
 
Table 4: Site-wise distribution 
Site No of patients Percentage 
Oral cavity 9 29.97% 
Oropharynx 9 29.97% 
Hypopharynx 9 29.97% 
Larynx 3 9.99% 
 
Table 5: Histology Distribution 
Differentiation No of patients Percentage 
Well Differentiated 4 13.32% 
Mod. Differentiated 19 63.27% 
Poorly Differentiated 7 23.37% 
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HEMATOLOGICAL TOXICITIES IN INDUCTION CHEMOTHERAPY: 
 All the patients enrolled in the study received 3 cycles of Paclitaxel, 
Cisplatin and 5 FU with all the necessary precautions and pre medications. 
The significant hematological toxicities encountered during the induction 
phase were graded with RTOG grading and CTCAE V.4. 
 
WBC: 
 There were two cases of Febrile Neutropenia/Grade 4 toxicity during 
the induction phase. They were treated with admission and the following 
supportive care: 
1. Empirical broad spectrum antibiotics. 
2. IV Fluids. 
3. G-CSF 300 mcg D1-5. 
All patients were kept under admission till they became apyrexial 
and clinically stable for at least 24 hours and the WBC counts returned to 
normal. 
However there was grade 3 toxicity in 11 patients (36.67%). The 
patients with grade 3 toxicity during the nadir period were just observed 
with no intervention and allowed to recover on their own. When the next 
evaluation of blood parameters were done for the next cycle of 
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chemotherapy,  if still grade 3 toxicity persisted then intervention was done 
with the delivery of 3 days of  Inj. G-CSF 300 mcg s.c. After the blood 
WBC levels were restored to normalcy, the next step in the management 
was followed. These patients were given primary prophylaxis with G-CSF 
during subsequent chemotherapy cycles. 
Hemoglobin: 
 Anemia was not a significant problem in the present study with most 
of the patients presenting with only grade 2 toxicity. They recovered with 
nutritional supplements. Grade 3 toxicity was seen only in 3 patients 
requiring transfusion with compatible packed cells to restore the normal 
levels. 
Platelets:  
 Thrombocytopenia was also not a significant problem with only 8 
patients having grade 1 platelet toxicity according to RTOG grading and all 
others having no platelet suppression. None needed intervention. 
 
NAUSEA: 
 Since Cisplatin a highly emetogenic agent was part of the treatment 
schedule, nausea and vomiting were a significant problem. 22 patients 
(73.26%) had grade 2 nausea which required continuous antiemetic 
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measures. And 4 patients had grade 3 nausea which prompted intervention. 
They were managed with  
1. IV fluids to correct dehydration, if any. 
2. Metoclopramide 40 mg PO every 4–6 hours for 4 days.  
3. Dexamethasone 4-8 mg IV BD for 4 days.  
 
DIARRHOEA: 
 Diarrhea is a common complication in any paclitaxel and 5 FU 
containing regimen. The present study had grade 3 or 4 toxicity in 2 
patients out of 30. (6.67%). The grade 3 and grade 4 reactions were 
managed by plenty of fluid intake, and IV fluids in case of severe 
dehydration not corrected by oral rehydration alone. Antispasmodics and 
anti-motility agents were used to reduce the frequency of stools and to 
manage the abdominal cramps and pain. Regular monitoring of the 
biochemical parameters was done.  
 
DELAY IN CHEMOTHERAPY. 
 There was a significant delay in delivering the next cycle of 
chemotherapy due to toxicity management in 13 patients (43.29%). 
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However there was no undue delay of more than 3 days in any of the 
patients. 
 
G-CSF REQUIREMENT: 
 G-CSF was required in 9 patients for normalizing the WBC levels 
before the next cycle of chemotherapy and as primary prophylaxis in the 
subsequent cycles when they needed G-CSF in previous cycles. All were 
used in only grade 3 and grade 4 patients. Two of the patients had grade 4 
toxicity / febrile neutropenia     
 
Graph 8: G-CSF Requirement 
 
 
 
 
Graph 9: Time delay in Induction Chemo 
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TOXICITY IN RADIOTHERAPY: 
 Radiotherapy was delivered in conventional fractionation of 2 Gy 
per day over 5 days a week to a total dose of 66 – 70 Gy. The toxicities 
encountered during radiotherapy were graded using RTOG acute morbidity 
scoring criteria. 
Mucositis:  
 Majority of the patients developed grade 2 mucositis (19 patients).  
3 patients had grade 3 toxicities and treatment had to be suspended 
to allow for the resolution of mucositis before proceeding with further 
radiation. 
The mucositis were managed with,  
1. Inj. Dexamethasone 8 mg IV BD 
2. Soda Bicarbonate Mouth Wash every 3-4 hours. 
3. Alcohol free Antibacterial Mouthwash / oral lozenges. 
4. Dispersible pain killer tablets to relieve pain.  
Dysphagia: 
 Most of them developed grade 2 dysphagia during treatment (14 
patients, 50.4%) they were managed with pain killer and maintained on 
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nutritious liquid diet. 5 patients developed grade 3 reactions and had to be 
maintained on nutrition by either IV Fluids or NG tube feeding. 
Dermatitis: 
 This was not a significant problem with this study. Most of them had 
grade 1 and grade 2 reactions which did not warrant any treatment breaks 
and were allowed to resolve by itself after the completion of treatment. 
Salivary gland toxicity: 
 Almost all of them developed grade 2 toxicity by the time of first 
assessment (27 patients). But none had acute necrosis of the salivary gland. 
All of those who had xerostomia were prescribed artificial salivary 
supplements.  
 
DELAY IN RADIOTHERAPY:  
 Nearly one third of the patients did not complete the entire course of 
the radiotherapy within the stipulated time. 9 patients had treatment delays 
due to toxicities like mucositis and dysphagia (30%).  
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WEEKLY CDDP: 
 All the patients received weekly Cisplatin during radiotherapy. Two 
thirds of the patients (n=20) received at least 5 cycles of weekly 
chemotherapy. The rest received at least 4 cycles of chemotherapy. None 
of the patients received less than 4 cycles. There was significant nausea 
due to the chemotherapy with 18 patients developing grade 2 nausea and 5 
developing grade 3 nausea, which warranted intervention. They were 
managed with  
1. IV fluids to correct dehydration, if any. 
2. Metoclopramide 40 mg PO every 4–6 hours for 4 days.  
3. Dexamethasone 4-8 mg IV BD for 4 days.  
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Table 6: Toxicities during Treatment 
Grade 0 1 2 3 4 
WBC 0 3 
(9.99%) 
14 
(46.62%) 
11 
(36.67%) 
2 
(6.67%) 
PLATELET 22 
(73.26%) 
8 
(26.64%) 
0 0 0 
Hb 6 
(19.98%) 
4 
(13.32%) 
17 
(56.61%) 
3 
(9.995) 
---- 
NAUSEA 
IN 
INDUCTION 
0 4 22 
(73.26%) 
4 
(13.32%) 
----- 
MUCOSITIS 0 6 
(21.6%) 
19 
(68.4%) 
3 (10.8%) 0 
DYSPHAGIA 0 9 
(32.4%) 
14 
(50.4%) 
5 
(18%) 
0 
DERMATITIS 0 22 
(79.2%) 
6 
(21.6%) 
0 0 
SALIVARY 
GLAND 
0 1 
(3.6%) 
27 
 
----- 0 
NAUSEA IN 
RT 
0 5 
(18%) 
18 
(64.8%) 
5 
(185) 
0 
 
 
 Graph 11: Toxicity during Radiotherapy 
 
 
 
Graph 12: Delay during Radiotherapy 
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RESPONSE ASSESSMENT: 
Following Induction: 
 The response was assessed following induction therapy with 
thorough clinical examination and imaging studies. All the patients had a 
clinically evaluable response after the induction chemotherapy. 9 of the 30 
patients had a complete response at both the primary and nodal site 
(29.97%). 
 Subset analysis shows that 6/19 moderately differentiated and 3/7 
poorly differentiated cancers achieved a complete response following 
induction chemotherapy. N3 nodes had a very good response rates with 5 
out the 7 patients achieving complete response. The hypo pharyngeal 
cancers had the maximum benefit from the chemotherapy (n=4). 
Following Entire treatment: 
 Following the completion of the entire treatment schedule of 
induction chemotherapy and the concurrent chemo radiation, the response 
rates were evaluated.  
 There was complete at the primary site in 19 (63.27%) and complete 
response at the nodal sites in 24 patients (79.92%). 
The overall complete response rate at both the primary and the 
secondary nodal sites together was 19 (63.27%).  
70 
 
Table 7: Factors affecting Response 
Factors Complete response Partial Response 
T 1 2 0 
T2 7 0 
T3 4 (80%) 1 (20%) 
T4 6 (42.85%) 8 (57.14%) 
N2 12 (75%) 4 (25%) 
N3 5 (71.43%) 2 (28.57%) 
Oral Cavity 4 (44.44%) 5 (55.56%) 
Oropharynx 6 (85.71%0 1 (14.29%) 
Hypopharynx 8 (88.88%) 1 (11.11%) 
Larynx 1 (33.33%) 2 (66.67%) 
Stage III 13 (81.25%) 3 (18.75%) 
Stage IV 6 (50%) 6 (50%) 
Well Diff 0 4 (100%) 
Mod. Diff 12 (70.5%) 5(29.41%) 
Poorly Diff 6 (85.71%) 1(14.29%) 
Delay in RT 4 (44.44%) 5 (55.56%) 
No Delay In RT 15 (78.95%) 4 (21.05%) 
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ANALYSIS OF THE RESPONSE RATES: 
Site and Response: 
 With regard to the site of involvement, nearly half of the oral cavity 
patients had only a partial response, 4 out of the 9 patients. In the case of 
oropharynx and hypopharynx, the response rates were near complete.   6 
out of the 7 oropharynx cases and 8 out of the 9 hypo pharyngeal cancers 
achieved complete response. The oropharyngeal and hypo pharyngeal 
malignancies significantly fared better compared to the buccal mucosa and 
laryngeal cases (p=0.015).  
TNM and Response: 
 T1 and T2 had 100% complete response rates and there was one 
failure in T3 disease. It was in the T4 group the results were poor. There 
was complete response in 6 out of the 14 patients (42.8%). 5 out 7 N3 node 
patients had a complete response, a success rate of 71.42% (p=0.6). When 
comparing the response rates between T3 and T4, there was no statistically 
significant difference between them (p=0.18). But when comparison was 
done between T1 and T2 taken together with T3and T4 taken together, 
there was significantly better response in the earlier group (p=0.01). 
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Stage & Response: 
 When analyzed with regard to the stage grouping, Stage III patient 
had complete response in 13 of the 16 patients who underwent complete 
treatment. Whereas in stage IV, only 50% had a complete response, of the 
total of 12 patients who completed the intended treatment. However this 
difference in the response was not significant. (p=0.09) 
Histology: 
 The complete response rate was very good in the case of poorly 
differentiated cancers with 85.71% (6/7).  Also, in moderately 
differentiated cancers too, the response rates were good with 12 out the 
total 17 achieving CR. However, there was no statistical difference 
between the response rates of the moderately and poorly differentiated 
tumors (p=0.4). Whereas, all the well differentiated cancers had a partial 
response. (p=0.01) 
Delay in RT: 
 Those who had a delay in the completion of the course of 
radiotherapy, more than half of them had a partial response (5 out 9, 
55.56%) (p=0.08). In other ways, in those achieving a complete response 
only 4 out the total 19 had a delay in RT (21.05%). 
 
 Graph 13: Response after Induction Chemotherapy 
 
 
Graph 14: Response after Entire Treatment 
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6. DISCUSSION 
  The results of the present study show that sequential therapy is 
feasible in our setup and should be considered in select cases of locally 
advanced head and neck cancers.   
  The study included a wide range of patients across the age groups 
between the eligibility ages of 18 years to 70 years. The study population 
was heavily dominated by males with only 3 females. But this was 
probably due to higher exposure to carcinogens as males are more 
commonly users of cigarettes, beedis and the other smokeless tobacco 
forms like pan, khaini etc. 
 The study also included a very good sample of all the sites in the 
head and neck region. A good representation of all TNM stages of head 
and neck cancers were included. 
 All the patients started on the protocol completed the entire course of 
three cycles of the induction chemotherapy. This compliance for induction 
phase of the trial is similar to other trials in the available literature. But two 
patients did not proceed onto radiotherapy following the completion of 
induction phase. The probable reason for these patients defaulting was due 
to the alleviation of symptoms or due to the adverse effects of 
chemotherapy.  
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This implies indirectly that it is important to select cases carefully 
for this regimen. Patients with good nutritional status at the start of the 
treatment are perhaps better suited to undergo the rigors of this intense 
treatment regimen better. The patients should be counseled clearly before 
the start of the treatment that radiotherapy is the essential part of treatment 
and has to delivered at the right time after induction chemotherapy or else 
the benefits of chemotherapy will be lost. Probably literacy will play a 
major role in this regard with literate people being able to grasp the 
consequences of defaulting radiotherapy. Economic factors also have to be 
taken into account in our country as this prolonged treatment process may 
take a heavy toll on the family. Most commonly the patient, a male, turns 
out to be the sole bread winner of the family and if he is repeatedly in 
hospital for the course of the treatment then the financial burden on the 
family becomes manifold and this prompts the patient to default treatment.  
In the TAX 324 study, almost all the patients concluded the entire 
induction phase in the TPF arm (98%). But only 79% of the patients in 
TPF arm proceeded to receive the chemo radiotherapy. In the TAX 323 
study, nearly 25% discontinued the chemotherapy. But the most common 
reason quoted by the authors for discontinuation is progressive disease. In 
the present study, there were no cases of disease progression during the 
treatment course. 
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 The toxicity assessment of the induction phase reveals that the 
addition of paclitaxel to the induction regimen does significantly increase 
the toxicity profile of the treatment. But this was manageable provided 
careful monitoring of the blood parameters were done at various times 
during the treatment and appropriate interventions done.  
There were no deaths related to the chemotherapy in the study. The 
myelosuppression was mostly due to paclitaxel in the induction regimen. 
There were 2 cases of grade 4/ febrile neutropenia cases recorded in the 
trial. But there were no deaths recorded during the trial. Febrile 
neutropenia was 5.2% in the Tax 323 study and 4.8% in the Tax 324 study. 
Similar to TAX studies the grade 3 and grade 4 neutropenia were more 
common. The TAX studies too did not allow primary prophylaxis with G- 
CSF which probably resulted in a high incidence of grade 3 and grade 4 
neutropenia in those studies. So, appropriate modifications were done in 
the study protocol. The present study also denied primary prophylaxis with 
G-CSF during the first cycle of induction chemotherapy. But if they needed 
G-CSF before the start of the subsequent cycle of induction chemotherapy, 
they were given primary prophylaxis with G-CSF during the subsequent 
cycles. Thus there was no undue delay in the subsequent cycles of 
chemotherapy due to hematological toxicities. And also all the patients 
received the entire planned 3 cycles. Thus the hematological toxicities are 
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less likely to affect the planned treatment provided good supportive care is 
given and appropriate management of the toxicities are done. 
Paclitaxel did not result in any untoward allergic reactions in any of 
the patient but all patients were put on steroids as a precautionary measure. 
The induction regimen also included a highly emetogenic drug like 
Cisplatin. This resulted in grade 3 nausea in 4 patients which needed IV 
fluid administration. The TAX studies recorded grade 3 or grade 4 nausea 
in around 5% of the patients. The present recorded a 13.32% grade 3 
nausea but no cases of grade 4 nausea. The nausea was appropriately 
managed with IV fluids to correct dehydration and with antiemetic like 
metoclopramide and dexamethasone. 
The Tax 323 study had a grade 3 or grade 4 diarrhea in 5 out of 177 
patients (2.8%) and in TAX 324 study, 7 out of 251 patients (2.8%). The 
present study also had a similar rate of grade 3 or 4 reactions (6.67%0. 
These patients were appropriately managed. They were advised by plenty 
of fluid intake of 2-3L per day. IV fluids were administered in the case of 
severe dehydration which was not corrected by oral rehydration alone. 
Antispasmodics and anti-motility agents were used to reduce the frequency 
and to manage the abdominal cramps and pain. Regular monitoring of the 
biochemical parameters like serum electrolytes and renal function tests 
were done. 
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The study revealed the advantages of induction chemotherapy 
followed by concurrent chemo radiation in locally advanced head and neck 
cancers.  
There was 30% complete response (CR) rate following the 
completion of the induction phase. This was similar to the 17% and 8.5% 
complete response rates seen in the TAX studies following induction TPF 
chemotherapy which was significantly higher than the comparative arm of 
PF induction therapy. 
This advantage was more in the case of N3 nodes with most 
responding by the end of the induction phase. Probably N3 nodes would 
benefit the most from the sequential chemo radiation. Also the sub sites of 
hypopharynx and oropharynx had the best response to the entire treatment 
protocol. And this was significant when compared to the response rates of 
the other sub sites of oral cavity and the larynx (p=0.015). This probably 
points to the role of induction chemotherapy in organ preserving therapy.  
 The toxicities encountered during radiotherapy and concurrent 
chemotherapy did not vary much from the regular upfront radiotherapy 
patients. Most of them received at least 4 cycles of the planned 6 cycles of 
weekly chemotherapy. 
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Unlike the TAX 323 study which delivered 4 different schedules of 
radiotherapy and similar to the TAX 324, radiation was delivered in 
conventional fashion of 2 Gy per fraction 5 days a week up to a total dose 
of 66 Gy. Since the non-inferiority of carboplatin to Cisplatin has not been 
proven beyond doubt in the concurrent setting, the present study delivered 
only Cisplatin as the concurrent chemotherapy.  
 The toxicity encountered during radiotherapy was stomatitis due to 
oral mucositis, dysphagia due to pharyngitis and esophagitis, dermatitis 
and dryness of mouth due to salivary gland toxicity. Three patients (~10%) 
had grade 3 mucositis which warranted suspension of radiation and 
intervention with steroids and mouthwash as discussed earlier in the results 
section. This was similar to the rates of stomatitis encountered in the TAX 
studies of 8.5% and 4.6% stomatitis. There were five cases of grade 3 
reactions of dysphagia which required IV fluids and NG tube feeding 
(17.9%). The parent study recorded a grade 3 dysphagia rate of 5.2%.  
 Both stomatitis and dysphagia are very important as they have 
serious implications regarding the time duration of treatment. It is a well-
known fact that even a delay of single day in completing the radiotherapy 
will have a considerable reduction in local control and disease free 
survival. So precautions were taken to prevent the development of grade 3 
toxicities by instituting steroids and regular mouthwash with soda bicarb 
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solutions and antibacterial solutions as described in the methodology of the 
protocol. 
 Since the radiation was delivered using only conventional 2D 
radiation fields with a Tele-Cobalt 60 machine, all the patients who 
underwent radiotherapy had xerostomia due to salivary gland toxicity. But 
none of the patients had serious complications like salivary gland necrosis.  
All those who developed xerostomia were prescribed artificial saliva.  
 Most of the patients also received at least 4 cycles of the planned 
weekly Cisplatin chemotherapy. However, there was significant toxicity 
like nausea to this schedule. They were managed with IV fluids and 
antiemetic as described above. 
 All these toxicities resulted in treatment breaks during radiotherapy 
in 9 patients out of the twenty eight who had undergone chemo radiation. 
(30%) 
 The overall complete response rates at the end of the entire schedule 
of the treatment was 63.27% (n=19). The TAX 323 study had recorded 
72% complete response rates among those who were started on the chemo 
radiation schedule.  
When analyzed with regard to site of involvement, the oral cavity 
patients had a very poor response to this regimen. Whereas the hypo 
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pharyngeal and oropharyngeal cancers had a near total complete response 
rate of 88.89% and 85.71% respectively. This better response in these two 
sub sites of the head and neck proved to be statistically significant 
(p=0.015).  
Differentiation which is probably a surrogate for the mitotic rate of 
the tumor cells showed a significant correlation with response rates with all 
4 well differentiated cancers resulting in partial responses (p=0.01). Most 
of them were buccal mucosa cancers. This implies that sequential therapy 
is not the best approach for buccal mucosa as most of the buccal mucosa 
cancers will be of well differentiated histology. But the poorly 
differentiated tumors and moderately differentiated tumors had a very good 
complete response rate of 85.71% and 70.6% respectively. (p=0.4)  
It has already been deduced that oropharyngeal and hypo pharyngeal 
cancers had a good response rate. This is probably due to the fact these 
sites will have more of moderate and poorly differentiated tumors. So, 
probably these are the two sub sites which will have the best response in a 
sequential therapy setting. But the other factors such as stage and 
nutritional status of the patient will also have an implication on the 
treatment outcome. 
It is a known fact that the T size of the primary will have an impact 
on the immediate loco regional control as well as the recurrence free 
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survival. The present study has confirmed the same fact with T1-T3 tumors 
achieving more complete responses. The lesser T stages T1 & T2 had a 
significantly better response rate when compared to the T3 & T4 stages 
(p=0.01). But this difference was not evident between the stages T3 & T4 
(p=0.18). Also the N3 node status had a very good response to this 
sequence with 5 out 7 resolving completely (71.42%). But this better 
response rate in the patients with N3 nodes was not statistically significant 
(p=0.6).  The prognostic significance of stage grouping is that involvement 
of nodes which upgrades the stage grouping to stage III reduces the 
survival by 50%. In the present study also stage III patients had a better 
response than the stage IV patients.   
 As already seen it is a known fact that even a single day of delay in 
the radiotherapy schedule is detrimental to the final outcome. More than 
half of those who had a delay in RT had partial responses as the outcome 
and this was statistically significant (p=0.08). In contrast in those who had 
a complete response only 21% had treatment breaks. 
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STRENGTHS OF THE STUDY: 
1. The study delivered the optimal induction chemotherapy regimen of 
three drugs containing a Taxane, Cisplatin and 5 FU. 
2. The definitive part of the treatment, concurrent chemo radiation was 
delivered following the induction phase. 
3. The optimal chemotherapy of Cisplatin was delivered during 
radiotherapy. 
4. All the toxicities were graded using standard scales like RTOG 
Acute Morbidity Scoring Criteria and Common Toxicity Criteria for 
Adverse Events Version 4. 
5. The response assessment was done using a standard scale of 
RECIST Criteria 1.1  
LIMITATIONS OF THE STUDY: 
1. The induction phase included paclitaxel instead of docetaxel which 
was part of the TAX studies and other phase III trials of induction 
chemotherapy. 
2. The radiation was delivered using 2D techniques. Delivering with 
3D conformal techniques would have been the optimal technique. 
3. There was no long term follow up of the patient which would have 
given the PFS and OS data for the sequential treatment. 
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4. The present study was a single arm study. A two arm comparative 
randomized study would have been better to settle the question of 
whether sequential therapy is better to upfront concurrent chemo 
radiation.   
  
 
 
CONCLUSION 
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7. CONCLUSION 
 In conclusion, head and neck cancers continue to be a public health 
problem afflicting the developing countries. And most of these patients are 
still presenting in the advanced stages. So, studies like the present one 
examining intensification of the treatment regimen to achieve better results 
needs to be carried out.  
 As for the present study, it shows the benefits of the sequential 
therapy with the inclusion of induction chemotherapy before the loco 
regional treatment. It shows response rates similar to other large 
randomized trials carried out to address the same question. Sequential 
therapy will be very useful in very carefully selected cases and needs to be 
carried out at a tertiary center with good supportive care. 
 Also the question of whether the present approach is superior to the 
standard treatment of concurrent chemo radiation upfront still stands 
unanswered. This has to be settled in large randomized trials with 
appropriate loco regional treatment as part of the sequential approach. 
Other questions that need to be addressed are the optimal number of 
chemotherapy cycles in the induction and the correct time to start loco 
regional treatment after the induction phase. 
 So to sum up, sequential therapy has a strong biological rationale. It 
reduces the tumor load before the start of the loco regional treatment. Also 
85 
 
when the tumor load becomes low, the proliferation rate of cancer cells is 
probably rapid. So incorporation of a loco regional treatment like chemo 
radiotherapy is likely to have a better control rate, as is the case with 
Induction chemotherapy followed by chemo radiotherapy.  
Sequential therapy is a feasible option for carefully selected patients 
with locally advanced head and neck cancers although with increased 
toxicity.  
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8. FUTURE DIRECTIONS 
The future considerations for sequential therapy are finding out the 
optimal combination of the induction regimen and concurrent chemo 
radiation so as to reduce the high toxicity levels and achieve maximum 
response. There have been efforts to include novel agents like EGFR 
inhibitor, cetuximab along with induction therapy. This could be tried in 
the sequential therapy to get better results. Several phase II trials have been 
completed showing promising results68. It needs to be validated in a phase 
III trial. 
 Other targeted agents like geftinib and erlotinib could also be 
explored in the induction chemotherapy setting. These too have been 
evaluated in phase II trials with promising results. 
 Selection of patients for induction chemotherapy could be done on 
the basis of biomarkers. A correlative study of TAX 32469 has shown that 
patients with low levels of beta tubulin II had a superior OS and PFS. This 
was more so in patients receiving docetaxel. This point to the fact it could 
be both a prognostic factor and a predictive factor for response to taxanes. 
 Other biomarker such as EGFR expression for cetuximab in the case 
of induction has not been useful, as this is almost universal in head and 
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neck cancers. So other biomarkers were looked. A phase II trial has low 
levels of VEGF and Interleukin 6 is associated with better control rates. 
 The other biomarker creating so much interest is HPV. HPV 
prognostication is known in the case of oropharyngeal cancers. HPV 
positive malignancies are associated with better response rates. This may 
preclude the need for intense therapy in such cases. But the extent to which 
the treatment can be less intensified is not yet known and needs to be 
verified.  
 The other method of prognosticating may be to use the response 
achieved to induction chemotherapy as the basis for the modality of the 
loco regional treatment. Response to chemotherapy may be taken as a 
surrogate marker for response to radiotherapy. 
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APPENDIX - IV 
Muha;r;rp jfty; jhs; 
 nrd;id ,uh[{t;fhe;jp muR nghJ kUj;Jtkidf;F tUk; 
Gw;WNeha; Nehahspapfsplk; fjph;tPr;R rpfpr;ir gw;wpa Muha;r;rp. 
 jiy kw;Wk; fOj;J gFjpapy; Kw;wpa Gw;WNeha;f;F gy tifahd 
fjph;tPr;R rpfpr;ir Kiwfs; cs;sd. Kjypy; Gw;WNeha; kUe;Jfshd 
“ghf;yplhf;nry;> rp];gpshl;lbd; kw;Wk; 5 GNshNuh Auhrpy;” Mfpatw;why; 
Nehapd; msit Fiwj;J gpwF jPtpu fjph;tPr;R rpfpr;irAld; thue;NjhUk; 
“rp];gpshl;bd;” kUe;J nfhLj;J Gw;WNehia Fzg;gLj;JtJ gw;wp 
Muha;tJ ,e;j Muha;r;rpapd; Nehf;fk;. 
 ePq;fSk; ,e;j Muha;r;rpapy; gq;Nfw;f tpUk;GfpNwhk;. ,e;j 
Muha;r;rpapy; jPtpu fjph;tPr;R rpfpr;ir mspj;J rpy rpwg;G ghpNrhjidf;F 
cl;gLj;jp mjd; jfty;fis Muha;Nthk.; mjdhy; jq;fspd; Nehapd; 
Ma;twpf;ifNah rpfpr;irNah ghjpg;G Vw;glhJ vd;gij njhptpj;Jf; 
nfhs;fpNwhk;. 
 KbTfis my;yJ fUj;Jf;fis ntspapLk; NghNjh my;yJ 
Muha;r;rpapd; NghNjh jq;fspd; ngaiuNah my;yJ milahsq;fisNah 
ntspapl khl;Nlhk; vd;gijAk; njhptpj;Jf; nfhs;fpNwhk;. 
 ,e;j rpwg;G ghpNrhjidfspd; KbTfisAk; Nehapd; jd;ik 
gw;wpAk; Muha;r;rpapd; NghJ my;yJ Muha;r;rpapd; Kbtpd; NghJ 
jq;fSf;F mwptpg;Nghk; vd;gijAk; njhptpj;Jf; nfhs;fpNwhk;. 
 
 
_______________________________                                       ________________________________ 
Muha;r;rpahsh; ifnahg;gk;    gq;Nfw;ghsh; 
ifnahg;gk; 
Njjp:    
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APPENDIX - V 
Muha;r;rp xg;Gjy; fbjk; 
jiy kw;Wk; fOj;J gFjpapy; Kw;wpa Gw;WNeha;f;F> “ghf;yplhf;nry;> 
rp];gpshl;lbd; kw;Wk; 5 GNshNuh Auhrpy;” Mfpatw;why; Nehapd; msit 
Fiwj;J gpwF jPtpu fjph;tPr;R rpfpr;irAld; thue;NjhUk; “rp];gpshl;bd;” 
kUe;J nfhLj;J nra;ag;gLk; Ma;T. 
ngah;:       Njjp    : 
taJ:       cs;/Gw Nehahsp vz;: 
ghy;:       Muha;r;rp Nrh;f;if vz; : 
  ,e;j Muha;r;rpapd; tptuq;fSk; mjd; Nehf;fq;fSk; KOikahf 
vsf;F njspthf tpsf;fg;gl;lJ. 
 vdf;F tpsf;fg;gl;l tp\aq;fis ehd; Ghpe;Jnfhz;L vdJ 
rk;kjj;ij njhptpf;fpNwd;. 
 vdf;F Gw;WNeha; ,Uf;Fk; gFjpapy; fjph;tPr;R rpfpr;ir nra;J 
nfhs;s rk;kjk;. 
 ,e;j muha;r;rpapy; gpwhpd; eph;ge;jkpd;wp vd; nrhe;j tpUg;gj;jpd; 
Nghpy; gq;F ngWfpNwd;. ,e;j Muha;r;rpapy; ,Ue;J ehd; ve;NeuKk; 
gpd;thq;fyhk; vd;gijAk; mjdhy; ve;j ghjpg;Gk; Vw;glhJ vd;gijAk; 
ehd; Ghpe;J nfhz;Nld;. 
 ehd; jiy kw;Wk; fOj;J gFjpapy; Kw;wpa Gw;WNeha; Fwpj;j ,e;j 
Ma;Tf;fhd tptuq;fs; nfhz;l jfty; jhisg; ngw;Wf; nfhz;Nld;. 
 vdf;F ,e;j muha;r;rpapd;gb jPtpu fjph;tPr;R rpfpr;ir kw;Wk; 
Gw;WNeha; kUe;Jfs; ngw;Wf; nfhs;s rk;kjk;. ,e;j Muha;r;rpf;F 
Njitahd gpw ghpNrhjidfs; nra;J nfhs;s rk;kjk;. 
 ,e;j muha;r;rpapdhy; Vw;gLk; ed;ikfisAk;> rpy 
gf;ftpisTfisAk; gw;wp njspthf kUj;Jth; %yk; njhpe;J nfhz;Nld;. 
 Ehd; vd;Dila RaepidTlDk; kw;Wk; KO Rje;jpuj;JlDk; ,e;j 
kUj;Jt Muha;r;rpapy; vd;id Nrh;j;Jf; nfhs;s rk;kjk;. 
 
  
         ifnahg;gk;  
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ETHICAL COMMITTEE CLEARANCE 
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